Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Sweeney

Showing results (51-60 of 264) with videos related to

Pageof 27
Sort By:
Clinical Genitourinary Cancer|October 11, 2017
Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary MalignanciesSarah E Wong, Scott A North, Christopher J Sweeney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Reply to L. Marandino et alMartin R Stockler, Andrew J Martin, Haryana M Dhillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malateNoah M Hahn, Maria Reckova, Liang Cheng, et al.
Endocrine-Related Cancer|November 26, 2024
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancerElahe A Mostaghel, Victoria Wang, Brett T Marck, et al.
Molecular Cancer Research : MCR|April 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR VariantsKatherine L Morel, Anis A Hamid, John G Clohessy, et al.
Future Oncology (London, England)|November 29, 2007
Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implicationsNoah M Hahn, Mark R Kelley, James E Klaunig, et al.
Prostate Cancer and Prostatic Diseases|January 8, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancerPraful Ravi, Wanling Xie, Silke Gillessen, et al.
Clinical Genitourinary Cancer|May 27, 2019
Body Mass Index and Outcomes in Germ-Cell TumorsBradley A McGregor, Rowan E Miller, Elizabeth O'Donnell, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2023
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized TreatmentAnis A Hamid, Nicolas Sayegh, Bertrand Tombal, et al.
The Prostate|March 9, 2010
A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen speciesRajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng, et al.
Pageof 27

Showing results (51-60 of 264) with videos related to

Sort By:
Pageof 27
Clinical Genitourinary Cancer|October 11, 2017
Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary MalignanciesSarah E Wong, Scott A North, Christopher J Sweeney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Reply to L. Marandino et alMartin R Stockler, Andrew J Martin, Haryana M Dhillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malateNoah M Hahn, Maria Reckova, Liang Cheng, et al.
Endocrine-Related Cancer|November 26, 2024
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancerElahe A Mostaghel, Victoria Wang, Brett T Marck, et al.
Molecular Cancer Research : MCR|April 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR VariantsKatherine L Morel, Anis A Hamid, John G Clohessy, et al.
Future Oncology (London, England)|November 29, 2007
Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implicationsNoah M Hahn, Mark R Kelley, James E Klaunig, et al.
Prostate Cancer and Prostatic Diseases|January 8, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancerPraful Ravi, Wanling Xie, Silke Gillessen, et al.
Clinical Genitourinary Cancer|May 27, 2019
Body Mass Index and Outcomes in Germ-Cell TumorsBradley A McGregor, Rowan E Miller, Elizabeth O'Donnell, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2023
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized TreatmentAnis A Hamid, Nicolas Sayegh, Bertrand Tombal, et al.
The Prostate|March 9, 2010
A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen speciesRajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng, et al.
Pageof 27